Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

被引：9
|
作者：
Grommes, Christian
Gavrilovic, Igor T.
Kaley, Thomas Joseph
Nolan, Craig
Omuro, Antonio Marcilio Padula
Wolfe, Julia
Pentsova, Elena
Hatzoglou, Vaios
Mellinghoff, Ingo K.
DeAngelis, Lisa Marie
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7515
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Grommes, Christian
    Kaley, Thomas Joseph
    Nolan, Craig
    Omuro, Antonio Marcilio Padula
    Wolfe, Julia
    Mellinghoff, Ingo K.
    DeAngelis, Lisa Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Grommes, C.
    Gavrilovic, I.
    Kaley, T.
    Nolan, C.
    Omuro, A.
    Wolfe, J.
    Pentsova, E.
    Hatzoglou, V.
    Mellinghoff, I. K.
    Deangelis, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)
    Grommes, Christian
    Gavrilovic, Igor
    Kaley, Thomas
    Nolan, Craig
    Omuro, Antonio
    Wolfe, Julia
    Pentsova, Elena
    Hatzoglou, Vaios
    Mellinghoff, Ingo
    DeAngelis, Lisa
    NEURO-ONCOLOGY, 2016, 18 : 3 - 4
  • [4] Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)
    Renaud, Loic
    Bossard, Jean-Baptiste
    Terriou, Louis
    Cambier, Nathalie
    Chanteau, Guillaume
    Carpentier, Benjamin
    Barbieux, Sarah
    Wemeau, Mathieu
    Hieulle, Julia
    Boyle, Eileen M.
    Morschhauser, Franck
    BLOOD, 2020, 136
  • [5] Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Renaud, Loic
    Bossard, Jean Baptiste
    Carpentier, Benjamin
    Terriou, Louis
    Cambier, Nathalie
    Chanteau, Guillaume
    Escure, Guillaume
    Tilmont, Remi
    Barbieux, Sarah
    Wemeau, Mathieu
    Hieulle, Julia
    Boyle, Eileen M.
    Morschhauser, Franck
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (03) : 370 - 373
  • [6] Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
    Grommes, C.
    Pentsova, E.
    Nolan, C.
    Wolfe, J.
    Mellinghoff, I. K.
    Deangelis, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] PHASE II STUDY OF SINGLE AGENT BUPARLISIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)
    Grommes, Christian
    Pentsova, Elena
    Nolan, Craig
    Wolfe, Julia
    Mellinghoff, Ingo
    DeAngelis, Lisa
    NEURO-ONCOLOGY, 2016, 18 : 3 - 3
  • [8] Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma
    Christian, Grommes
    Thomas, Kaley
    Abdel-Wahab, Omar
    Omuro, Antonio M.
    Ingo, Mellinghoff
    DeAngelis, Lisa
    BLOOD, 2015, 126 (23)
  • [9] Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)
    Grommes, Christian
    Gavrilovic, Igor
    Miller, Alexandra M.
    Stone, Jacqueline B.
    Kaley, Thomas
    Madzsar, Juli T.
    Schumpp, Alyssa
    Butler, Brittany T.
    Schaff, Lauren
    Mellinghoff, Ingo K.
    BLOOD, 2019, 134
  • [10] Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
    Grommes, Christian
    Pastore, Alessandro
    Gavrilovic, Igor
    Kaley, Thomas
    Nolan, Craig
    Omuro, Antonio M.
    Wolfe, Julia
    Pentsova, Elena
    Hatzoglou, Vaois
    Mellinghoff, Ingo
    DeAngelis, Lisa
    BLOOD, 2016, 128 (22)
12345